Claimed effect · Tirzepatide

Does Tirzepatide help with obstructive sleep apnoea?

A
Grade A — established in humans2 RCTs · effect size: moderate
Short answerEstablished in humans. 2 RCTs point the same way: a moderate effect. SURMOUNT-OSA: apnoea–hypopnoea index fell by roughly 25–30 events per hour vs 5–6 on placebo; basis of the 2024 approval.

What the studies show

SURMOUNT-OSA: apnoea–hypopnoea index fell by roughly 25–30 events per hour vs 5–6 on placebo; basis of the 2024 approval.

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
    Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA).N Engl J Med, 2024;391:1193–1205Two trials, 469 adults; basis of the sleep-apnoea approval.

In context

Tirzepatide is a once-weekly peptide that activates both GIP and GLP-1 receptors. It is approved for type 2 diabetes, weight management and obstructive sleep apnoea, and in the only direct head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks) with a similar side-effect profile. It is a prescription medicine; versions sold outside that channel are unlicensed.

Tirzepatide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Tirzepatide proven to help with obstructive sleep apnoea?
Yes, as far as human trials can show it: 2 RCTs. LYO grades this outcome A.
What studies are behind the grade?
SURMOUNT-OSA: apnoea–hypopnoea index fell by roughly 25–30 events per hour vs 5–6 on placebo; basis of the 2024 approval.
Is Tirzepatide approved for this?
Tirzepatide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Tirzepatide

Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →